Skinvisible, Inc.
SKVI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.03 | 0.10 | 0.03 |
| FCF Yield | -4.63% | -22.75% | 9.29% | 32.45% |
| EV / EBITDA | 59.84 | -13.71 | -94.58 | 19.93 |
| Quality | ||||
| ROIC | 16.81% | 17.09% | 8.15% | -8.06% |
| Gross Margin | -2.19% | 100.00% | 98.28% | 99.50% |
| Cash Conversion Ratio | 0.12 | 0.03 | -0.04 | -0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | -58.47% | -68.88% | 0.45% | 148.63% |
| Free Cash Flow Growth | 8.60% | -302.84% | -87.95% | 1,119.88% |
| Safety | ||||
| Net Debt / EBITDA | 46.11 | -12.91 | -83.98 | 14.64 |
| Interest Coverage | -0.88 | -0.26 | -0.21 | 0.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -14,928.36 | 485.30 | -91,220.29 | -114,992.76 |